Brief: SymBio Pharmaceuticals says approval in Japan of anti-cancer drug TREAKISYM intravenous infusion 25 mg
28/09/2016 07:37
Sept 28 (Reuters) - SymBio Pharmaceuticals Ltd 4582.T :
* Says TREAKISYM Intravenous Infusion 25 mg, a standard
low-dose product of the anti-cancer drug TREAKISYM is approved
for manufacturing and marketing in Japan
Source text in Japanese: https://goo.gl/vdyuvV
Further company Coverage: 4582.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: qiujing.li.thomsonreuters.com@reuters.net))